Abstract
Glycosphingolipid lysosomal storage diseases are a small but challenging group of human disorders to treat. Although these appear to be monogenic disorders where the catalytic activity of enzymes in glycosphingolipid catabolism is impaired, the presentation and severity of disease is heterogeneous. Treatment is often restricted to palliative care, but in some disorders enzyme replacement does offer a significant clinical improvement of disease severity.
An alternative therapeutic approach termed “substrate deprivation” or “substrate reduction therapy” (SRT) aims to reduce cellular glycosphingolipid biosynthesis to match the impairment in catalytic activity seen in lysosomal storage disorders. N-Alkylated imino sugars are nitrogen containing polyhydroxylated heterocycles that have inhibitory activity against the first enzyme in the pathway for glucosylating sphingolipid in eukaryotic cells, ceramide-specific glucosyltransferase. The use of N-alkylated imino sugars to establish SRT as an alternative therapeutic strategy is described in cell culture and gene knockout mouse disease models. One imino sugar, N-butyl-DNJ (NB-DNJ) has been used in clinical trials for type 1 Gaucher disease and has shown to be an effective and safe therapy for this disorder. The results of these trials and the prospects of improvement to the design of imino sugar compounds for treating Gaucher and other glycosphingolipid lysosomal storage disorders will be discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Allende, M.L. and Proia, R.L., 2002, Lubricating cell signaling pathways with gangliosides, Curr Opin Struct Biol. 12:587–592.
Andersson, U., Butters, T.D., Dwek, R.A., and Platt, F.M., 2000, N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo, Biochem Pharmacol 59:821–829.
Butters, T.D., Dwek, R.A., and Platt, R.M., 2000a, Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disorders, Chem Rev. 100:4683–4696.
Butters, T.D., Dwek, R.A., and Platt, F.M., 2003a, therapeutic applications of imino sugars in lysosomal storage disorders, Curr Top Med Chem. 3:561–574.
Butters, T.D., Mellor, H.R., Narita, K., Dwek, R.A., and Platt, F.M., 2003b, Small Molecule Therapeutics for the Treatment of Glycolipid Lysosomal Storage Disorders, Phil Trans R Soc Lond B 358:927–945.
Butters, T.D., van den Broek, L.A.G.M., Fleet, G.W.J., Krulle, T.M., Wormald, M.R., Dwek, R.A., and Platt, F.M., 2000b, Molecular requirements of imino sugars for the selective control of N-linked glycosylation and glycosphingolipid biosynthesis, Tetrahedron:Asymmetry. 11:113–124.
Cox, T., Lachmann, R., Hollak, C., Aerts, J., van Weely, S., Hrebicek, M., Platt, F., Butters, T., Dwek, R., Moyses, C., Gow, I., Elstein, D., and Zimran, A., 2000, Novel oral treatment of Gaucher’s Disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis, Lancet. 355:1481–1485.
Dwek, R.A., Butters, T.D., Platt, F.M., and Zitzmann, N., 2002, targeting glycosylation as a therapeutic approach, Nature Rev Drug Discovery. 1:65–75.
Freeze, H.H., 2002, Human disorders in N-glycosylation and animal models, BBA Gen Subjects. 1573:388–393.
Gadola, S.D., Zaccai, N.R., Harlos, K., Shepherd, D., CastroPalomino, J.C., Ritter, G., Schmidt, R.R., Jones, E.Y., and Cerundolo, V., 2002, Structure of human CD1b with bound ligands at 2.3 angstrom, a maze for alkyl chains, Nat Immunol. 3:721–726.
Gagnon, M. and Saragovi, H.U., 2002, Gangliosides: therapeutic agents or therapeutic targets?, Expert Opin Ther Patents. 12:1215–1223.
Jeyakumar, M., Butters, T.D., CortinaBorja, M., Hunnam, V., Proia, R.L., Perry, V.H., Dwek, R.A., and Platt, F.M., 1999, Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin, Proc Nat Acad Sci USA. 96:6388–6393.
Jeyakumar, M., Butters, T.D., Dwek, R.A., and Platt, F.M., 2002a, Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis, Neuropathol Appl Neurobiol. 28:343–357.
Jeyakumar, M., Norflus, F., Tifft, C.J., CortinaBorja, M., Butters, T.D., Proia, R.L., Perry, V.H., Dwek, R.A., and Platt, F.M., 2001, Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation, Blood. 97:327–329.
Jeyakumar, M., Smith, D., EliottSmith, E., CortinaBorja, M., Reinkensmeier, G., Butters, T.D., Lemm, T., Sandhoff, K., Perry, V.H., Dwek, R.A., and Platt, F.M., 2002b, An inducible mouse model of late onset Tay-Sachs disease, Neurobiol Disease. 10:201–210.
Kobayashi, T. and Hirabayashi, V., 2000, Lipid membrane domains in cell surface and vacuolar systems, Glycoconjugate J. 17:163–171.
Kolter, T. and Sandhoff, K., 1999, Sphingolipids—their metabolic pathways and the pathobiochemistry of neurodegenerative diseases, Angew Chem Int Ed. 38:1532–1568.
Marek, K.W., Vijay, I.K., and Marth, J.D., 1999, A recessive deletion in the GlcNAc-1-phosphotransferase gene results in peri-implantation embryonic lethality, Glycobiology. 9:1263–1271.
Marks, D.L., Wu, K.J., Paul, P., Kamisaka, Y., Watanabe, R., and Pagano, R.E., 1999, Oligomerization and topology of the Golgi membrane protein glucosylceramide synthase, J Biol Chem. 274:451–456.
Mellor, H.R., Nolan, J., Pickering, L., Wormald, M.R., Platt, F.M., Dwek, R.A., Fleet, G.W.J., and Butters, T.D., 2002, Preparation, biochemical characterization and biological properties of radiolabelled N-alkylated deoxynojirimycins, Biochem J. 366:225–233.
Platt, F.M. and Butters, T.D., 1998, New therapeutic prospects for the glycosphingolipid lysosomal storage diseases, Biochem Pharmacol. 56:421–430.
Platt, F.M. and Butters, T.D., 2000, Substrate deprivation: A new therapeutic approach for the glycosphingolipid lysosomal storage diseases, Expert Reviews in Molecular Medicine () 1–17.
Platt, F.M., Neises, G.R., Dwek, R.A., and Butters, T.D., 1994a, N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis, J Biol Chem. 269:8362–8365.
Platt, F.M., Neises, G.R., Karlsson, G.B., Dwek, R.A., and Butters, T.D.,1994b, N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing, J Biol Chem. 269:27108–27114.
Platt, F.M. Neises, G.R., Reinkensmeier, G., Townsend, M.J., Perry, V.H., Proia, R.L., Winchester, B., Dwek, R.A., and Butters, T.D., 1997a, Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin, Science. 276:428–431.
Platt, F.M., Reinkensmeier, G., Dwek, R.A., and Butters, T.D., 1997b, Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin, J Biol Chem. 272:19365–19372.
Priestman, D.A., Platt, F.M., Dwek, R.A., and Butters, T.D., 2000, Imino sugar therapy for type I Gaucher disease, Glycobiology. 19:iv–vi.
Sawkar, A.R., Cheng, W.C., Beutler, E., Wong, C.H., Balch, W.E., and Kelly, J.W., 2002, Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease, Proc NatAcad Sci USA. 99:15428–15433.
Suzuki, K., Proia, R.L., and Suzuki, K., 1998, Mouse models of human lysosomal diseases, Brain Path. 8:195–215.
Yamashita, T., Wada, R., Sasaki, T., Deng, C.X., Bierfreund, U., Sandhoff, K., and Proia, R.L., 1999, A vital role for glycosphingolipid synthesis during development and differentiation, Proc Nat Acad Sci USA. 96:9142–9147.
Zimran, A., 1997, Gauchers Disease, London, Bailliere Tindall.
Zimran, A. and Elstein, D., 2003, Gaucher disease and the clinical experience with substrate reduction therapy, Phil Trans R Soc Lond B 358:961–966.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this paper
Cite this paper
Butters, T.D., Dwek, R.A., Platt, F.M. (2003). New Therapeutics for the Treatment of Glycosphingolipid Lysosomal Storage Diseases. In: Axford, J.S. (eds) Glycobiology and Medicine. Advances in Experimental Medicine and Biology, vol 535. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0065-0_14
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0065-0_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4908-2
Online ISBN: 978-1-4615-0065-0
eBook Packages: Springer Book Archive